This could be a once-in-a-lifetime convergence... ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
FG CDMG GT Bio Internal Email Series - #4
by Jason Williams / december 1, 2025 Are you prepared for the coming avalanche and tidal wave? Dear Reader, A $246 Billion cancer avalanche is coming this way! The National Cancer Institute estimates that nearly 60% of cancer diagnoses and 70% of cancer deaths occur in patients aged 65 and older. The American Cancer Society projects new cancer cases in the United States to rise from roughly 1.9 million in 2024 to 2.4 million by 2040, an increase of nearly 30%. And the financial burden of cancer care explodes. The American Association for Cancer Research reports that U.S. spending on cancer treatment will reach $246 billion by 2030: cutting-edge therapies can exceed $750,000 per course of treatment. There is a profit tidal wave coming, too. Those costs build the pressure for new treatments that result in better outcomes at lower prices. This confluence of the cancer avalanche, with its skyrocketing cost, and the rise in the number of older people, creates a dynamic tidal wave of opportunity for revolutionary companies and early investors. I've discovered one company that stands out from the crowd. Their revolutionary cancer immunotherapy platform allows the body’s own defenses to kill cancer cells. They check all the boxes investors want — scalability, speed, and cost efficiency — yet still trades for less than the price of a single Big Pharma lab instrument. Click here for the full story. To your wealth,  Jason Williams Investment Director, Future Giants You signed up for our newsletter with the email indra21poetra@gmail.com. You can manage your subscription and get our privacy policy here. This email is from Angel Publishing, 3 East Read Street, Baltimore, MD 21202 © Wealth Daily. |
|
| |
Tidak ada komentar:
Posting Komentar